News headlines about Flex Pharma (NASDAQ:FLKS) have been trending somewhat positive on Tuesday, according to Accern Sentiment. The research group rates the sentiment of media coverage by reviewing more than twenty million blog and news sources. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Flex Pharma earned a daily sentiment score of 0.19 on Accern’s scale. Accern also gave news headlines about the biotechnology company an impact score of 45.2873323279082 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the stock’s share price in the immediate future.
A number of research firms have issued reports on FLKS. Zacks Investment Research lowered shares of Flex Pharma from a “hold” rating to a “sell” rating in a research note on Wednesday, January 3rd. Roth Capital reaffirmed a “buy” rating and issued a $12.00 price target on shares of Flex Pharma in a research note on Wednesday, January 3rd. Finally, Cantor Fitzgerald reaffirmed a “hold” rating and issued a $10.00 price target on shares of Flex Pharma in a research note on Monday, September 25th. One analyst has rated the stock with a sell rating, one has assigned a hold rating and three have issued a buy rating to the company. Flex Pharma currently has an average rating of “Hold” and an average price target of $9.35.
Shares of Flex Pharma (FLKS) opened at $4.60 on Tuesday. The firm has a market cap of $82.67 and a P/E ratio of -2.28. Flex Pharma has a one year low of $2.68 and a one year high of $5.93.
Flex Pharma (NASDAQ:FLKS) last issued its quarterly earnings results on Monday, November 6th. The biotechnology company reported ($0.54) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.60) by $0.06. Flex Pharma had a negative net margin of 2,655.19% and a negative return on equity of 71.39%. The company had revenue of $0.41 million during the quarter, compared to analyst estimates of $0.47 million. research analysts predict that Flex Pharma will post -2.39 EPS for the current year.
ILLEGAL ACTIVITY NOTICE: This piece of content was first reported by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are reading this piece of content on another website, it was illegally copied and republished in violation of US and international copyright & trademark laws. The correct version of this piece of content can be viewed at https://www.dispatchtribunal.com/2018/01/09/flex-pharma-flks-given-daily-media-impact-score-of-0-19.html.
Flex Pharma Company Profile
Flex Pharma, Inc is a biotechnology company. The Company develops treatments for nocturnal leg cramps, muscle cramps and spasms associated with severe neuromuscular conditions, and exercise associated muscle cramps (EAMCs). The Company’s product candidates activate certain receptors in primary sensory neurons, which then act through neuronal circuits to reduce the repetitive firing, or hyperexcitability, of alpha-motor neurons in the spinal cord, thereby preventing or reducing the frequency and intensity of muscle cramps and spasms.
Receive News & Ratings for Flex Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Flex Pharma and related companies with MarketBeat.com's FREE daily email newsletter.